comparemela.com

Latest Breaking News On - Tammy groene - Page 3 : comparemela.com

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

MINNEAPOLIS, Feb. 15, 2024 Panbela Therapeutics, Inc. , , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today.

United statesTammy groeneNasdaq stock marketNasdaq hearings panelPanbela therapeutics incEuropean unionNasdaq listing rulesPrivate securities litigation reform actAnnual reportQuarterly reportsCurrent reports

Panbela Announces Closing of Approximately $9 0 Million Public Offering

MINNEAPOLIS, Feb. 01, 2024 Panbela Therapeutics, Inc. , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today.

United statesTammy groeneNasdaq stock marketExchange commissionRoth capital partnersEuropean unionPanbela therapeutics incPublic warrantsCapital partnersClemente driveNewport beachPrivate securities litigation reform actAnnual reportQuarterly reportsCurrent reports

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

MINNEAPOLIS, Jan. 30, 2024 Panbela Therapeutics, Inc. , a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced.

United statesTammy groeneJohns hopkins university school of medicinePanbela therapeutics incAmerican association for cancer researchNasdaq stock marketEuropean unionAmerican associationCancer researchJohns hopkins university schoolMolecular therapeuticsNovel antitumor agentsPrivate securities litigation reform actAnnual reportQuarterly reportsCurrent reports

Panbela Announces Pricing of Approximately $9 0 Million Public Offering

MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today

United statesTammy groeneExchange commissionEuropean unionNasdaq stock marketPanbela therapeutics incRoth capital partnersCommon warrantsCapital partnersClemente driveNewport beachPrivate securities litigation reform actAnnual reportQuarterly reportsCurrent reports

Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO,

MINNEAPOLIS, Jan. 18, 2024 (GLOBE NEWSWIRE) Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs

University of pennsylvaniaUnited statesUnited kingdomTammy groeneElizabeth bruckheimerMichael hogartyNasdaq stock marketEuropean unionAdvances in neuroblastoma therapy consortiumPanbela therapeutics incChildren oncology group phaseBritish journalNew advancesNeuroblastoma therapy consortiumVice presidentChief scientific officer

vimarsana © 2020. All Rights Reserved.